Program
Voriconazole
Also written as “voriconazole”, “voriconazole (Vfend)” and “oral voriconazole”.
Its studies are mostly in Aspergillosis · Mycoses · Invasive Fungal Infections · Candidemia · Candidiasis, led by 3 companies.
Drug pageVoriconazole: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 200 open or running | phase 4since Aug 31, 2005 | Aug 25, 2005 | none ahead |
| Yung Shin Pharm. Ind.its history only | 20 open or running | phase 4since Sep 21, 2016 | Sep 21, 2016 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 1since Dec 13, 2015 | Dec 13, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Aug 25, 2005.
- Feb 6, 2006Phase 4 study in Invasive Fungal InfectionsNCT00288197 · 77 enrolled · China
- Feb 9, 2006Phase 3 study in Antifungal Prophylaxis of Invasive Fungal InfectionsNCT00289991 · 489 enrolled · Canada, Czech Republic, Egypt and more
- Mar 7, 2006Phase 4 study in MycosesNCT00300677 · 12 enrolled · United States
- Oct 19, 2007Phase 4 study in CandidemiaNCT00548262 · 54 enrolled · Brazil, Chile, Colombia and more
- Nov 9, 2007Phase 2 study in PharmacokineticsNCT00556998 · 26 enrolled · United States
- Feb 8, 2008Phase 4 study in AspergillosisNCT00620074 · 6 enrolled · United States
- Mar 27, 2008Phase 4 study in CandidiasisNCT00647907 · 7 enrolled · Taiwan
- May 29, 2008Phase 3 study in Candidiasis, InvasiveNCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
- Aug 20, 2008Phase 2 study in CandidiasisNCT00739934 · 40 enrolled · United States
- Feb 3, 2009Phase 3 study in Invasive AspergillosisNCT00836875 · 31 enrolled · United States, Canada, Czechia and more
- Mar 2, 2009Phase 1 study in Healthy VolunteersNCT00855101 · 35 enrolled · Belgium
- Jul 13, 2009Phase 4 study in AspergillosisNCT00940017 · 24 enrolled · United States
- Mar 10, 2010Phase 3 study in CandidiasisNCT01092832 · 23 enrolled · China, Czech Republic, Hong Kong and more
- Jun 27, 2011Phase 2 study in AspergillosisNCT01383993 · 21 enrolled · Japan
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
All 20 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01383993Aspergillosis · Japan | 2 | Completed | May 2013 | 21 |
| NCT01092832Candidiasis · China, Czech Republic, Hong Kong and more | 3 | Terminated | May 2013 | 23 |
| NCT00940017Aspergillosis · United States | 4 | Completed | Oct 2008 | 24 |
| NCT00855101Healthy Volunteers · Belgium | 1 | Completed | Jul 2009 | 35 |
| NCT00836875Invasive Aspergillosis · United States, Canada, Czechia and more | 3 | Terminated | May 2013 | 31 |
| NCT00739934Candidiasis · United States | 2 | Completed | Oct 2009 | 40 |
| NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more | 3 | Completed | May 2010 | 216 |
| NCT00647907Candidiasis · Taiwan | 4 | Completed | 7 | |
| NCT00620074Aspergillosis · United States | 4 | Terminated | Feb 2009 | 6 |
| NCT00556998Pharmacokinetics · United States | 2 | Completed | Dec 2009 | 26 |
| NCT00548262Candidemia · Brazil, Chile, Colombia and more | 4 | Completed | Oct 2009 | 54 |
| NCT00300677Mycoses · United States | 4 | Completed | Aug 2008 | 12 |
| NCT00289991Antifungal Prophylaxis of Invasive Fungal Infections · Canada, Czech Republic, Egypt and more | 3 | Completed | Feb 2009 | 489 |
| NCT00288197Invasive Fungal Infections · China | 4 | Completed | Jun 2007 | 77 |
| NCT00174473Neutropenia | 2 | Completed | 49 | |
| NCT00159822Aspergillosis · France | 3 | Completed | Dec 2008 | 48 |
| NCT00150345Neutropenia · Germany | 3 | Completed | Apr 2009 | 147 |
| NCT00150319Renal Insufficiency · United States | 2 | Terminated | Oct 2005 | 1 |
| NCT00143312Invasive Fungal Infections · Belgium, France, Germany and more | 4 | Completed | Apr 2008 | 45 |
| NCT00136968Mycoses | 1 | Completed | 12 |
How it is read
Names in the registry
- “Voriconazole”, 13 entries
- “voriconazole”, 7 entries
- “voriconazole (Vfend)”, 3 entries
- “oral voriconazole”, 1 entry
- “Vaway”, 1 entry
Conditions, from the studies’ own filings
- Aspergillosis, 7 studies
- Mycoses, 3 studies
- Invasive Fungal Infections, 3 studies
- Candidemia, 3 studies
- Candidiasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.